- Pattern Recognition
- GlueHunter 1.0
- LeadHunter 2.0
- ERST-LAB
Pattern Recognition
AI Technology
ERSTEQ’s pattern recognition platform deciphers structural and dynamic signatures—analyzing surface complementarity, conformational shifts, and dynamic binding interfaces—to predict biologically relevant interactions and unlock undruggable targets.
Proprietary pattern recognition technology optimized for the evolving landscape of novel therapeutic modalitiesGlueHunter 1.0
AI-Powered Rational Molecular Glue Discovery PlatformGlueHunter1.0 integrates two specialized engines that accelerate the discovery Neo-degradable targets and molecular glues/PPI modulators through complementary pattern recognition analysis
-
1Neo-substrate Identification
Analyzes surface interactions, target recruitment and anchoring factors, and structural complementarity to identify novel neo-substrates with high therapeutic potential. -
2Molecular Glue Discovery
Extracts geometric and topological features, maps 3D conformational changes, and profiles dynamic binding interfaces to enable the rational design of tailored molecular glues.
Applications
Enables the end-to-end discovery of molecular glue degraders and
stabilizers, the identification of novel neo-substrates, and the design of
PPI modulators to precisely regulate protein–protein interactions, driving
therapeutic innovation across oncology, neurodegeneration, and other disease areas.
LeadHunter 2.0
Target-centric, Motion & Motility-driven Drug Discovery Platform
LeadHunter 2.0 analyzes therapeutically actionable patterns through atomic-level assessment of three-dimensional structural data,
powered by the dynamic conformational changes of target proteins.
This approach goes beyond static models to reveal
hidden opportunities for drug intervention.
-
1Hot Spot Identification
Evaluates binding affinity, functional and disease-associated mechanisms, and structural complementarity to pinpoint functionally relevant binding sites with high druggability. -
2Motion & Motility Analysis
Profiles geometric and topological features, captures 3D conformational changes, and maps dynamic binding interfaces to uncover previously inaccessible regulatory sites.
Applications
Enables the discovery of small molecule regulators—including inhibitors
and activators—designed to precisely modulate target protein function.
ERST- LAB
Full-cycle (end-to-end, from in silico to in vivo) validation is delivered from molecule to animal, with real-time feedback integrated into the AI drug discovery platform—powering smarter, faster drug discovery. In addition, the validation system provides target-specific, high-precision efficacy assessment to support confident decision-making in drug development.
Rapid, Continuously improving of Drug discovery
